PRENETICS GLOBAL LTD-CL A (PRE)
KYG722451229 - Common Stock
We assign a fundamental rating of 3 out of 10 to PRE. PRE was compared to 117 industry peers in the Health Care Providers & Services industry. The financial health of PRE is average, but there are quite some concerns on its profitability. PRE is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PRE had negative earnings in the past year.
In the past 5 years PRE always reported negative net income.
PRE had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
PRE's Return On Assets of -25.50% is on the low side compared to the rest of the industry. PRE is outperformed by 77.59% of its industry peers.
PRE's Return On Equity of -31.41% is on the low side compared to the rest of the industry. PRE is outperformed by 60.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.5% | ||
| ROE | -31.41% | ||
| ROIC | N/A |
ROA(3y)-28.89%
ROA(5y)-31.4%
ROE(3y)-37.26%
ROE(5y)-47.44%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 42.48%, PRE is doing good in the industry, outperforming 70.69% of the companies in the same industry.
PRE's Gross Margin has been stable in the last couple of years.
PRE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.48% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.16%
GM growth 5YN/A
2. Health
2.1 Basic Checks
PRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRE has more shares outstanding
Compared to 1 year ago, PRE has an improved debt to assets ratio.
2.2 Solvency
PRE has an Altman-Z score of 1.58. This is a bad value and indicates that PRE is not financially healthy and even has some risk of bankruptcy.
PRE has a Altman-Z score (1.58) which is in line with its industry peers.
PRE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of PRE (0.00) is better than 87.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.58 |
ROIC/WACCN/A
WACC6.2%
2.3 Liquidity
PRE has a Current Ratio of 2.37. This indicates that PRE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.37, PRE belongs to the top of the industry, outperforming 82.76% of the companies in the same industry.
PRE has a Quick Ratio of 2.29. This indicates that PRE is financially healthy and has no problem in meeting its short term obligations.
PRE's Quick ratio of 2.29 is amongst the best of the industry. PRE outperforms 81.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.37 | ||
| Quick Ratio | 2.29 |
3. Growth
3.1 Past
PRE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.39%.
PRE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -83.19%.
Measured over the past years, PRE shows a very negative growth in Revenue. The Revenue has been decreasing by -30.65% on average per year.
EPS 1Y (TTM)-38.39%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-1146.67%
Revenue 1Y (TTM)-83.19%
Revenue growth 3Y-30.65%
Revenue growth 5YN/A
Revenue growth Q2Q-89.62%
3.2 Future
Based on estimates for the next years, PRE will show a very strong growth in Earnings Per Share. The EPS will grow by 104.07% on average per year.
PRE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 100.53% yearly.
EPS Next Y97.06%
EPS Next 2Y104.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year340.39%
Revenue Next 2Y100.53%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PRE. In the last year negative earnings were reported.
Also next year PRE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PRE's earnings are expected to grow with 104.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y104.07%
EPS Next 3YN/A
5. Dividend
5.1 Amount
PRE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PRENETICS GLOBAL LTD-CL A
NASDAQ:PRE (4/24/2024, 12:11:57 PM)
5.453
+0.88 (+19.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap66.58M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.5% | ||
| ROE | -31.41% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.48% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.37 | ||
| Quick Ratio | 2.29 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-38.39%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y97.06%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-83.19%
Revenue growth 3Y-30.65%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y